Latest headcount
2,500
YoY change
+12.1%
Headcount CAGR
+18.5%
Revenue / employee
$1.49M
Employee count history for Alnylam Pharmaceuticals
| Fiscal year | Employees |
|---|---|
| 2004 | 71 |
| 2005 | 94 |
| 2006 | 122 |
| 2007 | 129 |
| 2008 | 170 |
| 2009 | 178 |
| 2010 | 172 |
| 2011 | 116 |
| 2012 | 129 |
| 2013 | 165 |
| 2014 | 256 |
| 2015 | 369 |
| 2016 | 514 |
| 2017 | 749 |
| 2018 | 1,065 |
| 2019 | 1,323 |
| 2020 | 1,453 |
| 2021 | 1,665 |
| 2022 | 2,002 |
| 2023 | 2,100 |
| 2024 | 2,230 |
| 2025 | 2,500 |
Revenue per employee for Alnylam Pharmaceuticals
Annual revenue divided by reported headcount, normalized to US dollars.
| Fiscal year | Revenue per employee (USD) |
|---|---|
| 2004 | $60.3K |
| 2005 | $60.8K |
| 2006 | $221K |
| 2007 | $395K |
| 2008 | $566K |
| 2009 | $565K |
| 2010 | $582K |
| 2011 | $713K |
| 2012 | $517K |
| 2013 | $286K |
| 2014 | $198K |
| 2015 | $111K |
| 2016 | $91.7K |
| 2017 | $120K |
| 2018 | $70.3K |
| 2019 | $166K |
| 2020 | $339K |
| 2021 | $507K |
| 2022 | $518K |
| 2023 | $871K |
| 2024 | $1.01M |
| 2025 | $1.49M |
Earnings per employee for Alnylam Pharmaceuticals
Annual net income divided by reported headcount, normalized to US dollars; years with a net loss dip below zero.
| Fiscal year | Earnings per employee (USD) |
|---|---|
| 2004 | -$460K |
| 2005 | -$457K |
| 2006 | -$284K |
| 2007 | -$663K |
| 2008 | -$154K |
| 2009 | -$267K |
| 2010 | -$253K |
| 2011 | -$497K |
| 2012 | -$822K |
| 2013 | -$541K |
| 2014 | -$1.41M |
| 2015 | -$786K |
| 2016 | -$798K |
| 2017 | -$655K |
| 2018 | -$715K |
| 2019 | -$670K |
| 2020 | -$591K |
| 2021 | -$512K |
| 2022 | -$565K |
| 2023 | -$210K |
| 2024 | -$125K |
| 2025 | $125K |
Employee count history for Alnylam Pharmaceuticals (ALNY)
Annual figures come from annual reports (10-K, or 20-F/40-F for foreign filers); interim rows reflect headcount disclosed in periodic filings. Year-over-year change compares each filing with the prior year's equivalent. Revenue and earnings per employee are annual figures normalized to US dollars.
- 20252,500+12.1%
- 20242,230+6.2%
- 20232,100+4.9%
- 20222,002+20.2%
- 20211,665+14.6%
- 20201,453+9.8%
- 20191,323+24.2%
- 20181,065+42.2%
- 2017749+45.7%
- 2016514+39.3%
- 2015369+44.1%
- 2014256+55.2%
- 2013165+27.9%
- 2012129+11.2%
- 2011116-32.6%
- 2010172-3.4%
- 2009178+4.7%
- 2008170+31.8%
- 2007129+5.7%
- 2006122+29.8%
- 200594+32.4%
- 200471—
About Alnylam Pharmaceuticals's employee count
Alnylam Pharmaceuticals (ALNY) employed 2,500 people in fiscal year 2025, based on its most recent annual report. That headcount grew by +270 (+12.1%) from 2,230 a year earlier.
Across the 2004–2025 period, the company's reported workforce went from 71 to 2,500 employees — a compound annual growth rate (CAGR) of +18.5% per year.
Alnylam Pharmaceuticals generated about $1.49M of revenue and $125K of net income per employee in its latest annual period. Revenue and earnings per employee gauge how efficiently a company turns headcount into output, and are most telling when tracked over time or compared with peers in the same industry.
Frequently asked questions
Test yourself on ALNY
Employees — 10 rounds, every one of them ALNY against another company. Leave whenever you like.
Practice run — it doesn’t move your skill rating and doesn’t touch the leaderboards. Misses do go into your review queue.
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.